These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 38219798)
21. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Bays HE; Gadde KM Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915 [TBL] [Abstract][Full Text] [Related]
22. Topiramate for weight reduction in adolescents with severe obesity. Fox CK; Marlatt KL; Rudser KD; Kelly AS Clin Pediatr (Phila); 2015 Jan; 54(1):19-24. PubMed ID: 25027265 [TBL] [Abstract][Full Text] [Related]
23. Phentermine and topiramate extended-release for the obesity: new kids on the block. Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717 [TBL] [Abstract][Full Text] [Related]
24. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443 [TBL] [Abstract][Full Text] [Related]
25. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa. Dalai SS; Adler S; Najarian T; Safer DL Contemp Clin Trials; 2018 Jan; 64():173-178. PubMed ID: 29038069 [TBL] [Abstract][Full Text] [Related]
26. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE. Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358 [No Abstract] [Full Text] [Related]
27. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449 [TBL] [Abstract][Full Text] [Related]
28. Topiramate for Weight Management in Children With Severe Obesity. Berman C; Naguib M; Hegedus E; Vidmar AP Child Obes; 2023 Jun; 19(4):219-225. PubMed ID: 35767803 [No Abstract] [Full Text] [Related]
29. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808 [TBL] [Abstract][Full Text] [Related]
30. Combination phentermine/topiramate for obesity treatment in primary care: a review. Xiong GL; Gadde KM Postgrad Med; 2014 Mar; 126(2):110-6. PubMed ID: 24685974 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Tak YJ; Lee SY Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104 [TBL] [Abstract][Full Text] [Related]
32. Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement? Kolotkin RL; Gadde KM; Peterson CA; Crosby RD Qual Life Res; 2016 May; 25(5):1237-44. PubMed ID: 26446094 [TBL] [Abstract][Full Text] [Related]
33. New obesity agents: lorcaserin and phentermine/topiramate. Fleming JW; McClendon KS; Riche DM Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Calderon G; Gonzalez-Izundegui D; Shan KL; Garcia-Valencia OA; Cifuentes L; Campos A; Collazo-Clavell ML; Shah M; Hurley DL; Abu Lebdeh HS; Sharma M; Schmitz K; Clark MM; Grothe K; Mundi MS; Camilleri M; Abu Dayyeh BK; Hurtado Andrade MD; Mokadem MA; Acosta A Int J Obes (Lond); 2022 Mar; 46(3):555-563. PubMed ID: 34811486 [TBL] [Abstract][Full Text] [Related]
35. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Garvey WT Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843 [TBL] [Abstract][Full Text] [Related]
36. Phentermine plus topiramate in the treatment of obesity. Malgarini RB; Pimpinella G Lancet; 2011 Jul; 378(9786):125-6; author reply 126-7. PubMed ID: 21742167 [No Abstract] [Full Text] [Related]
37. Cost-Effectiveness Analysis of Qsymia for Weight Loss. Finkelstein EA; Kruger E; Karnawat S Pharmacoeconomics; 2015 Jul; 33(7):699-706. PubMed ID: 24986038 [TBL] [Abstract][Full Text] [Related]
38. Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting. Bomberg EM; Clark J; Rudser KD; Gross AC; Kelly AS; Fox CK Pediatr Obes; 2024 Aug; 19(8):e13143. PubMed ID: 38886982 [TBL] [Abstract][Full Text] [Related]
39. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia). Shyh G; Cheng-Lai A Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809 [TBL] [Abstract][Full Text] [Related]
40. Drug interventions for the treatment of obesity in children and adolescents. Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]